Ionis Pharmaceuticals | 10-Q: Quarterly report
Needham Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $55
Ionis Pharmaceuticals Analyst Ratings
Earnings Call Summary | Ionis Pharmaceuticals(IONS.US) Q1 2025 Earnings Conference
Ionis Pharmaceuticals: Strong Q1 Performance and Promising Outlook Drive Buy Rating
Ionis Pharmaceuticals | 8-K: Ionis reports first quarter 2025 financial results
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say
Research Alert: Ions Q1 Results Beat Expectations, Sales Guidance Raised By More Than 20%
Ionis Pharmaceuticals Q1 Net Loss Narrows as Revenue Increases; 2025 Revenue Guidance Raised
Ionis Pharmaceuticals Misses Q1 Revenue Estimates, Raises Full-year Outlook
Express News | Ionis Pharmaceuticals: On Track for Second Independent Launch With Donidalorsen Pdufa August 21, 2025
Ionis Pharmaceuticals GAAP EPS of -$0.93 Beats by $0.20, Revenue of $132M Beats by $9.49M
Ionis Pharmaceuticals Raises 2025 View To Rev $725M-$750M >IONS
Press Release: Ionis Reports First Quarter 2025 Financial Results
Ionis Pharmaceuticals 1Q Loss/Shr 93c >IONS
Express News | Ionis Pharmaceuticals Q1 Operating Expenses USD 278 Million
Express News | Ionis Pharmaceuticals Q1 Adjusted Operating Income USD -117 Million Vs. IBES Estimate USD -175.9 Million
Express News | Ionis Pharmaceuticals Q1 Revenue USD 132 Million Vs. IBES Estimate USD 125.3 Million
Here's the Major Earnings Before the Open Tomorrow
New Harris Poll Findings Reveal HAE Patients Are Unsatisfied With Current Prophylactic Treatment Options, With Over 90% Interested in Trying New Therapies